1. Home
  2. TBPH vs INMD Comparison

TBPH vs INMD Comparison

Compare TBPH & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.97

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Logo InMode Ltd.

INMD

InMode Ltd.

HOLD

Current Price

$13.97

Market Cap

842.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
INMD
Founded
2013
2008
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
824.9M
842.0M
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
TBPH
INMD
Price
$16.97
$13.97
Analyst Decision
Buy
Hold
Analyst Count
6
5
Target Price
$18.40
$17.33
AVG Volume (30 Days)
307.5K
653.9K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
279.13
N/A
EPS
N/A
N/A
Revenue
$15,386,000.00
N/A
Revenue This Year
$8.46
$1.74
Revenue Next Year
N/A
$3.26
P/E Ratio
$8.25
$10.11
Revenue Growth
N/A
N/A
52 Week Low
$8.33
$12.72
52 Week High
$21.03
$16.74

Technical Indicators

Market Signals
Indicator
TBPH
INMD
Relative Strength Index (RSI) 59.74 47.19
Support Level $16.14 $13.32
Resistance Level $17.24 $14.70
Average True Range (ATR) 0.40 0.30
MACD 0.01 -0.07
Stochastic Oscillator 85.51 47.95

Price Performance

Historical Comparison
TBPH
INMD

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

About INMD InMode Ltd.

InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.

Share on Social Networks: